Darovasertib联合克唑替尼一线治疗转移性葡萄膜黑色素瘤:OptimUM-01研究的总生存、疗效与安全性
OptimUM-01是一项I/II期多中心开放标签研究,评估darovasertib联合克唑替尼一线治疗转移性葡萄膜黑色素瘤。44例初治患者中,客观缓解率为34.1%,疾病控制率(8周)为90.2%,中位无进展生存期7.0个月,中位总生存期21.1个月,安全性总体可控。
要点
- Darovasertib联合克唑替尼一线治疗mUM的ORR为34.1%,DCR(8周)为90.2%。
- 中位PFS为7.0个月,中位OS为21.1个月。
- 常见不良事件为腹泻、恶心、外周水肿和呕吐,3级及以上以肺栓塞和缺铁性贫血为主。
核心结论
- Darovasertib联合克唑替尼在初治mUM中显示出鼓舞人心的疗效,安全性可控,可能成为首类靶向治疗选择。
研究设计与样本
- OptimUM-01为I/II期、多中心、开放标签、剂量递增与扩展研究,纳入携带GNAQ/11突变的实体瘤患者,本次分析聚焦初治mUM的II期扩展队列,共44例。
主要发现
- 最常见不良事件为腹泻(95.2%)、恶心(84.1%)、外周水肿(61.4%)和呕吐(52.3%)。
- 最常见的3级及以上不良事件为肺栓塞(9.1%)和缺铁性贫血(6.8%)。
- 导致停药的不良事件发生于3例患者(6.8%)。
- 客观缓解率为34.1%,缓解持续时间为9.0个月,8周疾病控制率为90.2%。
- 中位无进展生存期为7.0个月(95% CI, 5.0 to 8.3),中位总生存期为21.1个月(95% CI, 11.9 to 20.7)。
关键数值与推荐
- 给药方案为darovasertib 300 mg每日两次联合克唑替尼200 mg每日两次。
- 入组标准包括RECIST v1.1可测量病灶、ECOG体能状态0-1及 adequate organ function。
临床怎么用
- 对于初治mUM患者,可考虑darovasertib联合克唑替尼作为靶向治疗选择,需监测腹泻、恶心、外周水肿、呕吐及肺栓塞等不良事件。
局限性
- 本研究为II期扩展队列,样本量有限(44例),未设随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Metastatic uveal melanoma (mUM) has poor prognosis with limited therapies. GNAQ/11 mutations that activate protein kinase C (PKC) are detected in 95% of UM tumors. Darovasertib is a first-in-class, oral, targeted PKC inhibitor that, in combination with the MET inhibitor crizotinib, has shown responses and encouraging survival outcomes in early mUM clinical trials. Here, we present phase 2 results in first-line patients with mUM treated with darovasertib 300 mg twice a day and crizotinib 200 mg twice a day. METHODS: The OptimUM-01 study was a phase I/II, multicenter, open-label, dose escalation and expansion study of darovasertib in patients with solid tumors harboring GNAQ/11 mutations irrespective of human leukocyte antigen status; this analysis focuses on the phase II expansion in previously untreated patients with mUM. Eligibility criteria included Response Evaluation Criteria in Solid Tumors v1.1 measurable disease, Eastern Cooperative Oncology Group performance status 0-1, and adequate organ function. Study end points included safety, objective response rate (ORR), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). RESULTS: Overall, 44 treatment-naïve patients were enrolled. The most common adverse events (AEs) were diarrhea (95.2%), nausea (84.1%), peripheral edema (61.4%), and vomiting (52.3%). The most common grade 3 or greater AEs were pulmonary embolism (9.1%) and iron deficiency anemia (6.8%). AEs leading to discontinuation occurred in three patients (6.8%). ORR was 34.1%, DOR was 9.0 months, and DCR was 90.2% at 8 weeks. The median PFS and OS were 7.0 months (95% CI, 5.0 to 8.3) and 21.1 months (95% CI, 11.9 to 20.7), respectively. CONCLUSION: Results from OptimUM-01 suggest that the combination of darovasertib and crizotinib has encouraging efficacy with a manageable safety profile and may represent a first-in-class targeted treatment option for patients with previously untreated mUM.
引用
- McKean M, Chmielowski B, Butler MO, et al. Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study. J Clin Oncol. 2026. PMID: 42950186. doi:10.1200/JCO-26-00802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。